Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891911745> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2891911745 abstract "7017 Background: TP53 mutations confer an adverse prognosis in patients (pts) with AML treated with standard chemotherapy. A recent study reported high response rates using a 10-day regimen of decitabine (DAC10) in pts with TP53-mutated ( TP53-MUT) AML. The question remains whether this benefit is unique to DAC10 or whether the same benefit among TP53-MUT AML applies to other low intensity therapy (Rx). Methods: We reviewed our own experience of pts treated with low intensity Rx from 2012 - 2016. Mutation testing was performed using a whole-exome sequencing panel. We reviewed the clinico-pathologic characteristics of these pts, and compared their outcomes based on the presence/absence of a TP53mutation and by the type of Rx they received. Results: There were 131 pts in our cohort of which 33 (25%) had TP53-MUT. Pt characteristics are outlined in Table 1A. All pts were treated with low intensity Rx and were divided into the following groups: DAC10 [n=34, 26%]; 5-day decitabine, or 7-day azacytidine (DAC5) [n=39, 30%]; or cladribine+low dose araC (CLAD/LDAC) [n=58, 44%]. Response rates and OS by Rx and TP53-MUT status are summarized in Table 1B. While there was no significant difference in response rates or OS by TP53-MUT status within any of the treatment approaches, there was a trend for inferior response rates and OS among pts with TP53-MUT who received either DAC-5 or CLAD/LDAC ; this was not seen in pts receiving DAC10. Conclusions: The presence of a TP53-MUT was associated with a nonsignificant trend towards inferior outcomes among pts receiving DAC5 or CLAD/LDAC, but not among those receiving DAC10. Comparing across groups, the CLAD/LDAC combination was associated with the longest OS, and DAC10 was associated with superior outcomes compared to DAC5, in TP53-MUT cohort. [Table: see text]" @default.
- W2891911745 created "2018-09-27" @default.
- W2891911745 creator A5000750846 @default.
- W2891911745 creator A5009603653 @default.
- W2891911745 creator A5010786159 @default.
- W2891911745 creator A5015101485 @default.
- W2891911745 creator A5020340537 @default.
- W2891911745 creator A5022647201 @default.
- W2891911745 creator A5049385583 @default.
- W2891911745 creator A5051949215 @default.
- W2891911745 creator A5054954794 @default.
- W2891911745 creator A5055045706 @default.
- W2891911745 creator A5059373442 @default.
- W2891911745 creator A5061026876 @default.
- W2891911745 creator A5079262854 @default.
- W2891911745 creator A5090435894 @default.
- W2891911745 date "2017-05-20" @default.
- W2891911745 modified "2023-10-15" @default.
- W2891911745 title "Outcomes with lower intensity therapy in TP53-mutated AML." @default.
- W2891911745 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7017" @default.
- W2891911745 hasPublicationYear "2017" @default.
- W2891911745 type Work @default.
- W2891911745 sameAs 2891911745 @default.
- W2891911745 citedByCount "0" @default.
- W2891911745 crossrefType "journal-article" @default.
- W2891911745 hasAuthorship W2891911745A5000750846 @default.
- W2891911745 hasAuthorship W2891911745A5009603653 @default.
- W2891911745 hasAuthorship W2891911745A5010786159 @default.
- W2891911745 hasAuthorship W2891911745A5015101485 @default.
- W2891911745 hasAuthorship W2891911745A5020340537 @default.
- W2891911745 hasAuthorship W2891911745A5022647201 @default.
- W2891911745 hasAuthorship W2891911745A5049385583 @default.
- W2891911745 hasAuthorship W2891911745A5051949215 @default.
- W2891911745 hasAuthorship W2891911745A5054954794 @default.
- W2891911745 hasAuthorship W2891911745A5055045706 @default.
- W2891911745 hasAuthorship W2891911745A5059373442 @default.
- W2891911745 hasAuthorship W2891911745A5061026876 @default.
- W2891911745 hasAuthorship W2891911745A5079262854 @default.
- W2891911745 hasAuthorship W2891911745A5090435894 @default.
- W2891911745 hasConcept C126322002 @default.
- W2891911745 hasConcept C143998085 @default.
- W2891911745 hasConcept C502942594 @default.
- W2891911745 hasConcept C71924100 @default.
- W2891911745 hasConceptScore W2891911745C126322002 @default.
- W2891911745 hasConceptScore W2891911745C143998085 @default.
- W2891911745 hasConceptScore W2891911745C502942594 @default.
- W2891911745 hasConceptScore W2891911745C71924100 @default.
- W2891911745 hasLocation W28919117451 @default.
- W2891911745 hasOpenAccess W2891911745 @default.
- W2891911745 hasPrimaryLocation W28919117451 @default.
- W2891911745 hasRelatedWork W2269936639 @default.
- W2891911745 hasRelatedWork W2396824931 @default.
- W2891911745 hasRelatedWork W2418422564 @default.
- W2891911745 hasRelatedWork W2534464466 @default.
- W2891911745 hasRelatedWork W2625234132 @default.
- W2891911745 hasRelatedWork W2889500728 @default.
- W2891911745 hasRelatedWork W2892053009 @default.
- W2891911745 hasRelatedWork W2944248311 @default.
- W2891911745 hasRelatedWork W2961722038 @default.
- W2891911745 hasRelatedWork W2963513172 @default.
- W2891911745 hasRelatedWork W2982026813 @default.
- W2891911745 hasRelatedWork W3025088295 @default.
- W2891911745 hasRelatedWork W3046622902 @default.
- W2891911745 hasRelatedWork W3082177268 @default.
- W2891911745 hasRelatedWork W3090882367 @default.
- W2891911745 hasRelatedWork W3116995261 @default.
- W2891911745 hasRelatedWork W3119742093 @default.
- W2891911745 hasRelatedWork W3155754818 @default.
- W2891911745 hasRelatedWork W3172808526 @default.
- W2891911745 hasRelatedWork W3088000764 @default.
- W2891911745 isParatext "false" @default.
- W2891911745 isRetracted "false" @default.
- W2891911745 magId "2891911745" @default.
- W2891911745 workType "article" @default.